The company has a few other foreign subsidiaries, which have reported losses in FY19. Bharat Forge Global Holding GmbH, Bharat Forge Kilsta AB, Mécanique Générale Langroise, and Bharat Forge PMT Technologie LLC have contributed to consolidated losses of the company.

Since registering a low on July 16, the bulls on Dalal Street are driving the markets higher as they have rallied close to 5 per cent. The early trend in SGX Nifty suggests that markets are on the verge for another positive opening.

The level of 11,180 is likely to act as immediate resistance and any move above this would result in a breakout of the channel. If Nifty sustains above this level, it may test the levels of 11,350-11,400 in the near term. Stocks in news: Sunteck Realty, BEML, Wipro, Info Edge.

BEML Limited informed the bourses on Tuesday that it has secured an order worth Rs 557 crore.  The acquisition wing of Ministry of Defence (MoD) has signed a contract with BEML for the procurement of 1,512 mine plough (MP) for tank T-90 S/SK

On Tuesday, the stock has formed ‘opening bullish Marubozu candle’, which indicates an extreme bullishness. Further, since the last two trading sessions, the volume is above the 50-day average, which is a sign of accumulation. The 14-period RSI on the daily timeframe has given a positive crossover and it is in bullish territory.

Continuing on Tuesday, bulls were witnessed maintaining their dominance over domestic benchmark indices as Sensex gained by 511.34 points or 1.37 per cent to close at 37,930.33 while Nifty rose by 140.05 points or 1.27 per cent to close at 11,162.25.

The debt-to-GDP ratio is attributable to the falling growth if it increases over four per cent. As a result of which, we would witness a contraction in the gross domestic product (GDP). Read on to find out more.

Tata Communications informed the exchanges on Tuesday that it has secured Type B licence in Kingdom of Saudi Arabia (KSA)

Jubilant Life Sciences announced that the company has received approval from Drug Controller General of India (DCGI) for manufacturing and marketing investigational antiviral drug Remdesivir for 100 mg/vial (lyophilized injection).

Since May 2020, it has witnessed a trend of the new order as the ports are now operational with the ease of the lockdown, worldwide. The quantity, however, still remains lower. Its order book as of the end of FY20 is at Rs 210 crore.